AD evidence-based medicine outcome instruments: how to better integrate patients’ preferences? Dear Colleagues, Dear Friends, A recently published study funded by Galderma investigates with the quantitative method named discrete choice experiment (DCE) the preference of patients and physicians when prescribing systemic treatments for AD. This DCE method is increasingly used in healthcare to elicit preferences […]
Read MoreISAD plans a celebration of the Centennial birthday anniversary of Georg RAJKA (1925-2013) next year in Melbourne, Australia Dear Colleagues, Dear Friends, Fleeing Hungary, his native country, after the Soviet occupation, Georg RAJKA made in Sweden then Norway an outstanding and very original academic career centered on Prurigo Besnier/AD. Prurigo Besnier was indeed the name […]
Read MoreAre dermatology professionals needed to balance the influence of TikTok and other social networks? Dear Colleagues, Dear Friends, The hashtag #topicalsteroidwithdrawal (TSW) got more than 600 million views on TikTok. A recent Lebanese study (doi: 10.2196/48389) did a great job by studying the content of this hashtag and by trying to alert our community on […]
Read MoreWhich research priorities for AD in 2024? Curative precision medicine vs preventive exposome-targeted medicine. Dear Colleagues, Dear Friends, In a recently published provocative perspective paper (DOI: 10.3389/fpubh.2024.1351732), Ian A. Myles, a NIH researcher, asks some good questions to our community which could help shaping our priorities. Currently, with the industry-led dramatic development of biologics and […]
Read More#RAJKA2024Doha #RAJKAMedal Dear Colleagues, Dear Friends, The abstract submission to the 14th Georg Rajka Symposium on AD (Doha, Qatar, October 24-26, 2024) closed as scheduled on July 15th. 149 abstracts from 32 countries were received. They are currently adjudicated, and the outcome will be available soon in second half of August. All accepted abstracts will be […]
Read MoreWhat PubMed tell us about current trends in AD research? Dear Colleagues, Dear Friends, Since the approval of dupilumab for severe adult AD by the FDA in 2017, published AD research has been tremendously driven by RCTs and associated research concerning dupilumab and other new systemic/ topical therapies designed to control TH2 inflammation. The influence […]
Read MoreThe 2024 Rajka Medal and Prize will be attributed, please have a look at the criteria to apply, this year will be very competitive! From 2024, an accompanying prize of 15.000 EUR will be given to the awardee to contribute to further research at his/her institution. In memory of Professor Georg RAJKA and his pioneering […]
Read MoreDear Colleagues, Dear Friends, Our May 2024 newsletter features ISAD collaboration with ILDS on the World Skin Health Day (WSHD) in Guinea and Madagascar, a national program to promote skin health including AD in Mauritania, the opening of the RAJKA2024 Call for Abstracts (ISAD Doha) and a focus on its pre-meeting: Patient-Centered Care in Atopic […]
Read MoreDear Colleagues, Dear Friends, Our April 2024 newsletter features report on our One Health event, our Research Fellowships and the RAJKA 2024 Symposium in Doha, along with a curated selection of the latest publications on PubMed that are worth reading. Alain TAÏEBPresident ISAD Examining Atopic Dermatitis through the One Health concept REPORT ON OUR SPRING […]
Read MoreDear Colleagues, Dear Friends, Our March 2024 newsletter highlights our upcoming One Health event, the RAJKA 2024 Symposium in Doha, along with a curated selection of the latest publications on PubMed that are worth reading. Alain TAÏEBPresident ISAD REGISTER NOW! Examining Atopic Dermatitis through the One Health concept VIRTUAL SYMPOSIUM Wed. April 17th 2024, 3-5 PM […]
Read More